Dr Reddy's stock has underperformed the sector so far this year. The stock is down around 21% vs 10% fall in Nifty pharma. With the further deterioration of Russina’s macroeconomic outlook, investor concerns are likely to remain high in the near term. This could lead to continued underperformance of the stock in the near term.
LONDON, July 4, 2021 /PRNewswire/ -- Shortly after the launch of its zero-fee policy in May this year, Huobi is pleased to announce an "Incentive Plan" for